Drug development for Rare cancers is challenging because it is difficult to obtain relevant data from very few patients. The oncology community is increasingly facing a disproportionate fraction of the total burden of cancers, hence, requiring multi-stakeholder cooperation and collaboration to complete rare cancer trials.
Nevertheless, new insights into the biology of rare cancers have led to an explosion in knowledge and the development of targeted agents. In addition, drug development strategies and the availability of new agents for rare cancers are at risk of stalling owing to the ever-increasing complexity and costs of clinical trials. Finding solutions . . .
Access the full-content and exclusive insights by registering to futurebridge.com.
Stay on top of your industry related trends and oppotunities.
Get insightful information access without any restrictions.
Learn about fundamental challenges confronted by your industry.
Gain access to all upcoming webinars and reply on-demand.
Share your focus area or question to engage with our Analysts through the Business Objectives service.Submit My Business Objective
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.
Tell us about your business objectives here
Share your key questions to connect with our analyst for a no-obligation consultation
Click here to see examples of business objectives